Key result
Dabigatran is linked to lower major bleeding, stroke, and mortality risks versus warfarin in NVAF.
Why the study?
Few studies have compared the effectiveness and safety among NOACs in patients with non-valvular AF.
Do non-vitamin K oral anticoagulants improve safety and clinical effectiveness compared to warfarin in patients with non-valvular atrial fibrillation?
Meta-Analysis
Do non-vitamin K oral anticoagulants improve safety and clinical effectiveness compared to warfarin in patients with non-valvular atrial fibrillation?
In real-world settings, dabigatran demonstrates superior safety and effectiveness compared to warfarin, and a better safety profile regarding major bleeding and intracranial hemorrhage compared to rivaroxaban in patients with non-valvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports preferring dabigatran over warfarin in non-valvular AF for safety and efficacy; confirms meta-analytic superiority on bleeding, stroke, and mortality.
BACKGROUND: The introduction of non-vitamin K antagonist oral anticoagulants (NOACs), with a non-inferior or superior clinical efficacy profile compared to vitamin K antagonists (VKAs), has significantly improved the safety profile and treatment adherence of patients with non-valvular atrial fibrillation (AF). However, few studies have compared the effectiveness and safety of NOACs. Therefore, we conducted this systematic review and network meta-analysis to compare the safety and clinical effectiveness of NOACs and VKAs in patients with non-valvular AF. METHODS: An online bibliographic search was conducted to retrieve real-world evidence studies published between January 2019 and June 2022. RESULTS: Dabigatran was associated with lower risks of major bleeding, ischemic stroke, and intracranial hemorrhage than warfarin. Among the NOACs, only dabigatran had a lower risk of all-cause mortality than warfarin. Dabigatran was also associated with lower risks of major bleeding and intracranial hemorrhage than rivaroxaban. CONCLUSION: Our meta-analysis confirms that dabigatran's real-world safety and clinical effectiveness align with the results of pivotal clinical trials.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2023) conducted a meta-analysis in non-valvular atrial fibrillation. NOACs (dabigatran, rivaroxaban) vs. Warfarin was evaluated on Major bleeding, ischemic stroke, intracranial hemorrhage, and all-cause mortality. Dabigatran was associated with lower risks of major bleeding, ischemic stroke, intracranial hemorrhage, and all-cause mortality than warfarin in patients with non-valvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: